EI
Eikon Therapeutics
EIKN13F as of Jun 30, 2026 · next update ~Nov 14
Limited coverage
Only 1 fund we track owns this stock, so quarterly sentiment and aggregates may be sparse.
Who's buying EIKN
Top funds mostly added to Eikon Therapeutics in Q2 (Apr–Jun)
Buying:
Funds1Insiders5Congress
- Top funds1 of 1 bought more, 0 sold some. Largest: Polen Capital Management, $466K (0% of its portfolio).
- Insiders5 insiders bought, 0 sales in 12 months.
- CongressNo trades disclosed in the last 12 months.
1 fund$466,433 held0.0% avg. weightQ2: 1 bought / 0 sold
13F reports are a snapshot as of Jun 30, 2026; funds may have traded since.
Share price · market data, not from 13F reports
Q2 2026
| Investor | Q2 change | ||
|---|---|---|---|
PC Polen Capital Management | $466,433 | <0.01% | New position |
| 1 fund | $466,433 |